Replimune

Replimune (operating at replimune.com) is a biotechnology company engineered to revolutionize cancer treatment through novel oncolytic immunotherapies. Founded in 2015 and headquartered in Woburn, Massachusetts, Replimune addresses the limitations of conventional cancer therapies by developing treatments designed to kill tumors locally, alter the tumor microenvironment, and ignite a systemic anti-tumor immune response. Under the hood, the company’s platform leverages a potent and versatile approach to activate durable, full-body immunity against solid tumors. This allows patients to benefit from a more effective and targeted treatment paradigm. Backed by significant funding, including a total of $140 million raised across multiple rounds, Replimune is advancing its mission to transform immunotherapy and improve outcomes for cancer patients.